1. Introduction

HBV drug resistance is the ability of hepatitis B virus (HBV) variants carrying specific genetic substitutions to replicate despite exposure to an antiviral drug at concentrations that would normally suppress susceptible virus.

It is primarily a consequence of:

• the high replication rate of HBV

• the error-prone nature of the viral polymerase/reverse transcriptase

• selection pressure exerted by antiviral therapy

• inadequate suppression of viral replication

Drug resistance is clinically important because it can result in:

• virological breakthrough

• persistent HBV DNA

• biochemical breakthrough

• progressive liver disease

• treatment failure

• selection of multidrug-resistant viral populations

2. Fundamental Concept

HBV polymerase has reverse transcriptase activity but lacks effective proofreading.

Therefore:

This population is often described as a:

Viral quasispecies

Most variants may be clinically insignificant.

However, when antiviral therapy applies selective pressure:

Mixed HBV population
        ↓
Antiviral therapy
        ↓
Susceptible variants suppressed
        ↓
Pre-existing resistant variants survive
        ↓
Selective expansion
        ↓
Increasing HBV DNA
        ↓
Virological breakthrough

3. Why HBV Develops Resistance

Resistance requires two major factors:

1. Genetic variation

HBV generates mutations during replication.

2. Selection pressure

Antiviral therapy suppresses susceptible variants preferentially.

The surviving resistant variants can subsequently become dominant.

4. The HBV Polymerase

The HBV polymerase contains several functional regions:

• terminal protein domain

• spacer region

• reverse transcriptase domain

• RNase H domain

Antiviral resistance mutations relevant to nucleos(t)ide analogues occur predominantly in:

Reverse transcriptase (RT) domain

5. HBV Genome Overlap

One of the most important concepts in HBV resistance is:

Therefore:

A mutation selected in polymerase

can potentially:

alter the surface antigen.

This has implications for:

• viral fitness

• serological detection

• vaccine escape

• transmission

• clinical phenotype

6. Genetic Barrier to Resistance

The genetic barrier is the number and/or nature of genetic changes required for clinically meaningful resistance to emerge.

Low genetic barrier

A single or small number of substitutions can produce resistance.

High genetic barrier

Multiple substitutions are generally required.

7. Major HBV Antivirals and Resistance Barrier

The major modern first-line agents are:

• tenofovir disoproxil fumarate (TDF)

• tenofovir alafenamide (TAF)

• entecavir

because of their potent antiviral activity and high resistance barriers.

8. First-Generation Nucleos(t)ide Analogues

Historically important agents include:

Lamivudine

Adefovir

Telbivudine

These drugs can select resistance relatively readily compared with current preferred high-barrier agents.

9. Lamivudine Resistance

Lamivudine resistance is one of the classic examples of HBV antiviral resistance.

The hallmark mutation is:

rtM204V/I

This occurs in the:

YMDD motif

of the reverse transcriptase domain.

10. YMDD Motif

The wild-type polymerase contains:

YMDD

motif.

Resistance-associated substitutions include:

rtM204V

or

rtM204I

Thus:

Wild type:
YMDD

Resistance:
YVDD
or
YIDD

These mutations reduce susceptibility to lamivudine.

11. Compensatory Mutation: rtL180M

Lamivudine resistance is frequently associated with:

rtL180M

together with:

rtM204V

The combination can restore some viral replication fitness while maintaining drug resistance.

A classic pattern is:

12. Lamivudine Resistance

Major mutation

rtM204V/I

Common compensatory mutation

rtL180M

Consequences

• marked reduction in lamivudine susceptibility

• virological breakthrough

• HBV DNA increase

Lamivudine resistance may also compromise susceptibility to some related agents because of overlapping resistance pathways.

13. Telbivudine Resistance

Telbivudine resistance is also strongly associated with:

rtM204I

and may involve:

rtL180M

Telbivudine therefore has a relatively low genetic barrier.

14. Adefovir Resistance

Important adefovir-associated substitutions include:

rtN236T

and:

rtA181T/V

These substitutions reduce susceptibility to adefovir.

15. rtA181T/V

This mutation is particularly interesting because the polymerase/S-gene overlap means that polymerase mutations may also generate changes in the surface protein.

Potential consequences include:

• altered viral fitness

• reduced antiviral susceptibility

• possible effects on HBsAg antigenicity

16. Entecavir Resistance

Entecavir has a:

high genetic barrier

in patients without previous nucleos(t)ide analogue resistance.

However, resistance can develop more readily in patients with:

pre-existing lamivudine resistance.

17. Entecavir Resistance Pathway

Entecavir resistance generally requires:

Primary resistance substitutions

such as:

• rtI169T

• rtT184G/S/A/I

• rtS202G/I

• rtM250V

together with:

pre-existing lamivudine-associated substitutions

particularly:

• rtL180M

• rtM204V/I

Thus:

Lamivudine resistance
        +
Additional entecavir-associated mutations
        ↓
Entecavir resistance

18. Tenofovir Resistance

Tenofovir has an extremely high genetic barrier to resistance.

Clinically significant confirmed resistance is:

exceedingly uncommon

with long-term therapy.

This is one of the major reasons tenofovir is a preferred therapy for chronic HBV.

Both:

• TDF

• TAF

provide potent HBV suppression.

19. Tenofovir Resistance — Important Distinction

Numerous HBV polymerase substitutions have been investigated for possible reduced susceptibility to tenofovir.

However:

Confirmed clinical resistance to tenofovir remains exceptionally rare.

Therefore, a rising HBV DNA during tenofovir treatment should first prompt assessment of:

1. adherence

2. treatment interruption

3. drug interactions/absorption issues where relevant

4. laboratory variation

5. other causes

before assuming resistance.

20. Why Tenofovir Has a High Genetic Barrier

Tenofovir:

• strongly suppresses HBV replication

• has potent antiviral activity

• requires substantial viral adaptation to overcome its effect

• has retained activity against many variants resistant to older agents

Thus:

21. Cross-Resistance

Resistance to one nucleos(t)ide analogue may affect susceptibility to another.

This is called:

Cross-resistance

Examples:

Lamivudine resistance

may compromise:

• telbivudine

• entecavir susceptibility

to varying degrees.

Therefore:

22. Why Treatment History Matters

Suppose a patient previously received:

Lamivudine

and developed:

rtM204V/I

Switching blindly to:

Entecavir

may allow selection of entecavir resistance because the lamivudine-resistant background lowers the genetic barrier.

Therefore:

23. Genetic Barrier vs Potency

These are different concepts.

Antiviral potency

How strongly the drug suppresses HBV replication.

Genetic barrier

How difficult it is for the virus to develop clinically relevant resistance.

An ideal antiviral has:

High potency + high genetic barrier.

24. Virological Breakthrough

A key clinical manifestation of resistance is:

Virological breakthrough

Typically defined as:

confirmed increase in HBV DNA by approximately ≥1 log₁₀ IU/mL from the lowest value achieved during treatment

after prior suppression/decline.

Definitions can vary slightly between guidelines.

25. Biochemical Breakthrough

This refers to:

re-elevation of ALT

after previous improvement or normalization during therapy.

Sequence may be:

Antiviral therapy
      ↓
HBV DNA falls
      ↓
ALT normalizes
      ↓
Resistance develops / adherence falls
      ↓
HBV DNA rises
      ↓
ALT rises

26. Serological Breakthrough

In some patients, virological changes may eventually be accompanied by changes in:

• HBeAg

• anti-HBe

• HBsAg

However:

HBV DNA is much more sensitive for detecting treatment failure.

27. Virological Breakthrough vs Resistance

These are not synonymous.

Virological breakthrough

A clinical/laboratory phenomenon.

Drug resistance

A biological mechanism involving reduced susceptibility due to viral genetic changes.

Virological breakthrough may result from:

• poor adherence

• treatment interruption

• drug resistance

• laboratory variation

Therefore:

28. Most Important Cause to Exclude First

In a patient whose HBV DNA begins to rise during treatment:

Check adherence first.

Ask about:

• missed doses

• medication access

• treatment interruptions

• side effects

• misunderstanding of dosing

• cost/access issues

29. When to Suspect Resistance

Consider resistance when:

• adherence is confirmed

• HBV DNA rises significantly

• there was prior suppression

• appropriate antiviral therapy is being taken

• breakthrough is reproducible

• previous antiviral exposure is present

30. Genotypic Resistance Testing

Resistance can be investigated by:

HBV polymerase gene sequencing

The relevant region of the HBV genome is amplified and sequenced.

Simplified workflow:

Patient serum
     ↓
HBV DNA extraction
     ↓
PCR amplification
     ↓
Polymerase/RT gene sequencing
     ↓
Sequence analysis
     ↓
Resistance-associated substitutions
     ↓
Interpretation with treatment history

31. Genotypic vs Phenotypic Testing

Genotypic testing

Identifies mutations associated with resistance.

Advantages:

• faster

• commonly used

• identifies known resistance mutations

Phenotypic testing

Measures viral susceptibility directly in vitro.

Advantages:

• assesses functional drug susceptibility

Limitations:

• technically complex

• expensive

• not routinely required in most clinical settings

32. Major Resistance Mutations

33. The YMDD Motif — Exam Favorite

Remember:

Lamivudine resistance

→ rtM204V/I

→ YMDD motif

Classic associated substitution:

rtL180M

This is one of the highest-yield HBV resistance facts.

34. Resistance and Viral Fitness

Not every resistance mutation produces a virus that replicates efficiently.

Some mutations:

reduce viral fitness.

Compensatory mutations may then arise.

Therefore:

Resistance mutation
       ↓
Reduced replication fitness
       ↓
Compensatory mutation
       ↓
Improved replication
       ↓
Stable resistant population

35. Resistance and HBV Quasispecies

HBV exists as a population of related variants.

Before treatment:

Wild type  █████████
Variant    ██
Variant    █
Variant    ██

After drug pressure:

Wild type  █
Resistant  █████████

Thus:

36. Factors Increasing Resistance Risk

Risk is increased by:

• low genetic barrier drug

• high baseline HBV DNA

• incomplete viral suppression

• prolonged exposure to ineffective therapy

• poor adherence

• prior antiviral therapy

• sequential monotherapy with inadequate agents

• inappropriate switching

37. Importance of Complete Viral Suppression

Persistent viral replication during therapy provides:

continued opportunity for selection of resistant variants.

Therefore:

38. Combination Therapy

Unlike HIV, routine combination therapy is not generally required for uncomplicated chronic HBV treated with modern high-barrier agents.

Current management typically relies on:

• tenofovir DF

• tenofovir AF

• entecavir

with selection based on patient-specific factors.

39. What to Do With Virological Breakthrough

A practical approach:

HBV DNA rises
      ↓
Repeat/confirm result
      ↓
Check adherence
      ↓
Review treatment history
      ↓
Assess timing and magnitude of rise
      ↓
Check ALT
      ↓
Consider resistance testing when appropriate
      ↓
Identify likely resistance pattern
      ↓
Select an effective high-barrier regimen

40. Avoiding Resistance

Use potent antiviral therapy

Prefer high-barrier agents.

Maintain adherence

Avoid unnecessary treatment interruptions.

Monitor HBV DNA

Identify incomplete suppression early.

Review previous treatment

Particularly prior lamivudine exposure.

Avoid ineffective sequential monotherapy

Especially when resistance is suspected.

41. Special Importance of Lamivudine Exposure

A history of lamivudine therapy should immediately trigger the question:

This matters particularly if considering:

Entecavir

because pre-existing lamivudine resistance substantially increases the risk of subsequent entecavir resistance.

42. Resistance and Occult Variants

Resistance mutations may exist as:

minority variants

below the detection threshold of routine sequencing.

Under treatment pressure they may expand.

This explains why:

43. Resistance and Surface Antigen

Because polymerase and surface genes overlap:

polymerase mutations can alter HBsAg.

Possible consequences include:

• altered antigenicity

• reduced antibody recognition

• vaccine escape

• diagnostic escape

These are particularly important from a microbiological and public-health perspective.

44. Diagnostic Escape

Some S-gene changes can reduce recognition of HBsAg by certain assays.

Possible consequences:

• false-negative or weakly reactive HBsAg

• occult infection phenotype

• transfusion risk

This is uncommon but conceptually important.

45. Vaccine Escape vs Drug Resistance

These should not be confused.

Vaccine escape

Usually involves changes in the:

surface antigen gene

and affects immune recognition.

Drug resistance

Primarily involves changes in:

polymerase reverse transcriptase

affecting antiviral susceptibility.

Because of genome overlap, however, the two phenomena can be genetically connected.

46. Resistance in Pregnancy

When antiviral prophylaxis is used during pregnancy, tenofovir is generally preferred because of:

• potent HBV suppression

• high genetic barrier

• extensive clinical experience

Monitoring remains important.

47. Resistance in Immunosuppression

HBV reactivation is not the same as antiviral resistance.

Reactivation

Previously controlled HBV becomes active again.

Resistance

HBV becomes less susceptible to an antiviral drug.

A patient can experience:

• reactivation without resistance

• resistance without reactivation

• both phenomena in complex cases

48. HBV Drug Resistance vs HIV Resistance

49. Clinical Scenario

Patient

Chronic HBV.

Previously treated with lamivudine.

HBV DNA initially suppressed.

After prolonged therapy:

HBV DNA rises significantly.

ALT subsequently increases.

Interpretation

Consider:

Lamivudine resistance

especially if mutations such as:

rtM204V/I ± rtL180M

are detected.

50. Another Clinical Scenario

Patient

On tenofovir.

HBV DNA:

<20 IU/mL

Later:

120 IU/mL

Patient admits missing several weeks of medication.

Interpretation

Do not immediately diagnose resistance.

Most likely first consideration:

treatment interruption/non-adherence.

51. Another Scenario

Patient

On entecavir.

Previous history:

prolonged lamivudine therapy with known resistance.

HBV DNA remains detectable/rises despite confirmed adherence.

Interpretation

Entecavir resistance should be considered because:

52. Key Resistance Concepts

Mutation

A genetic change.

Resistance-associated substitution

A mutation associated with reduced susceptibility.

Genetic barrier

Number/nature of changes needed to produce resistance.

Cross-resistance

Resistance affecting more than one drug.

Virological breakthrough

Significant HBV DNA rebound during therapy.

Biochemical breakthrough

ALT rebound following previous improvement.

Compensatory mutation

A mutation that improves replication fitness of a resistant virus.

53. Resistance Monitoring Algorithm

Patient receiving NA therapy
            ↓
Serial HBV DNA
            ↓
HBV DNA suppressed?
       ↙             ↘
     YES              NO/rising
      ↓                  ↓
Continue            Confirm result
monitoring               ↓
                    Assess adherence
                          ↓
                    Review treatment history
                          ↓
                     Repeat HBV DNA
                          ↓
                   Consider resistance
                          ↓
                 Genotypic testing
                          ↓
                Select active therapy

54. High-Yield Exam Pearls

Pearl 1

HBV resistance results from mutations in the viral polymerase/reverse transcriptase.

Pearl 2

HBV polymerase lacks effective proofreading.

Pearl 3

HBV exists as a genetically heterogeneous quasispecies.

Pearl 4

Lamivudine resistance is classically associated with:

rtM204V/I

Pearl 5

The classic motif is:

YMDD

Pearl 6

rtL180M commonly accompanies rtM204V.

Pearl 7

Adefovir resistance includes:

rtN236T

and:

rtA181T/V

Pearl 8

Entecavir resistance usually requires additional mutations on a background of lamivudine resistance.

Pearl 9

Tenofovir has a very high genetic barrier and clinically confirmed resistance is extremely rare.

Pearl 10

Virological breakthrough ≠ automatically drug resistance.

Pearl 11

Always check adherence first.

Pearl 12

Previous antiviral exposure strongly influences interpretation of resistance.

Pearl 13

HBV polymerase overlaps the S gene.

Pearl 14

Polymerase mutations can therefore affect HBsAg.

Pearl 15

High-barrier agents are preferred in modern HBV treatment.

55. One-Minute Revision

HBV Drug Resistance

Cause:

Error-prone HBV reverse transcription + antiviral selection pressure.

Major target:

HBV polymerase/reverse transcriptase.

Classic mutation:

rtM204V/I

Classic motif:

YMDD

Common compensatory mutation:

rtL180M

Adefovir:

rtN236T, rtA181T/V

Entecavir:

Requires additional resistance substitutions, particularly in the setting of pre-existing lamivudine resistance.

Tenofovir:

Very high genetic barrier; confirmed clinical resistance is exceedingly rare.

Most important first step in breakthrough:

Check adherence.

Resistance test:

Genotypic HBV polymerase sequencing when clinically appropriate.

Critical concept:

56. Final Take-Home Message

HBV drug resistance is fundamentally a story of:

Mutation → selection → expansion → virological breakthrough.

The classic pathway to remember is:

Lamivudine

↓

rtM204V/I

↓

YMDD alteration

↓

± rtL180M

↓

Lamivudine resistance

The modern solution is prevention:

For a patient with rising HBV DNA during treatment:

Do not immediately call it resistance.

First:

Confirm the result → check adherence → review treatment history → assess HBV DNA trend → consider genotypic resistance testing → modify therapy appropriately.

This approach prevents one of the most common errors in HBV management: confusing non-adherence with true antiviral resistance.

57. Standard References

1. World Health Organization. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection. Geneva: WHO; 2024.

2. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2025.

3. AASLD/IDSA. Current clinical guidance for hepatitis B.

4. Terrault NA, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B. Hepatology.

5. Locarnini S, Zoulim F. Molecular genetics of HBV drug resistance.

6. Fields Virology. Hepatitis B virus and antiviral resistance.

7. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases.

8. Jawetz, Melnick & Adelberg's Medical Microbiology.

9. Murray, Rosenthal & Pfaller. Medical Microbiology.

10. Sherris Medical Microbiology.

11. Major studies of HBV nucleos(t)ide analogue resistance and long-term antiviral therapy.

12. Current validated HBV genotypic resistance-testing methodologies and laboratory guidance.